Aijan Taalaibekova, Michelle Meyer, Stefanie Ulrich, Gulzada Mirzalieva, Maamed Mademilov, Mona Lichtblau, Cornelia Betschart, Talant M Sooronbaev, Silvia Ulrich, Konrad E Bloch, Michael Furian
{"title":"监测高海拔地区女性的性激素——一项初步研究。","authors":"Aijan Taalaibekova, Michelle Meyer, Stefanie Ulrich, Gulzada Mirzalieva, Maamed Mademilov, Mona Lichtblau, Cornelia Betschart, Talant M Sooronbaev, Silvia Ulrich, Konrad E Bloch, Michael Furian","doi":"10.3389/fgwh.2025.1544832","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The susceptibility to acute mountain sickness (AMS) in relation to sexual hormones in women remains elusive, partly because hormones could not be conveniently measured. We evaluated a novel kit for self-monitoring sexual hormones in women and recorded AMS incidence during high-altitude sojourns.</p><p><strong>Methods: </strong>Two groups of healthy, premenopausal women, mean ± SD age 23.1 ± 2.3 years, residing <1,000 m underwent baseline evaluations at 760 m before travelling to and staying for 2 days and nights (48 h) at 3,100 m or 3,600 m, respectively. Participants self-monitored morning urine sexual hormone concentrations (estrone-1-glucuronide, E1G, pregnanediol-3-alpha-glucuronide, PdG, and luteinizing hormone, LH) daily for 30d including altitude sojourns using the simple \"<i>Proov</i>\" kit (MFB Fertility Inc). Follicular and luteal menstrual cycle phases detected by LH peak, altitude-related adverse health effects (ARAHE), AMS [Lake Louise score 2018 (LLS) ≥ 3 points including headache] and pulse oximetry (SpO<sub>2</sub>) were assessed.</p><p><strong>Results: </strong>1,172 of 1,250 (93.8%) hormone measurements were successful, 78 of 1,250 (6.2%) failed due to nonadherence or technical failure. At 3,600 m, mean differences in urinary PdG concentration were 3.8 mcg/ml (95% CI, 0.6-7.1) between luteal and follicular cycle phases. At 3,100 m, corresponding difference was 8.5 mcg/ml (95% CI, 5.0-12.0). At 3,100 m, 9 of 21 (43%) women were diagnosed with AMS with SpO<sub>2</sub> of 93.0 ± 1.6% and LLS of 0.3 ± 1.4 in the morning after the first night. At 3,600 m, 12 of 21 (57%) women had AMS (<i>p</i> = 0.355 vs. 3,100 m) with SpO<sub>2</sub> of 86.8 ± 1.8% (<i>p</i> < 0.05 vs. 3,100 m) and LLS of 1.9 ± 1.4 (<i>p</i> < 0.05 vs. 3,100 m).</p><p><strong>Conclusion: </strong>Self-monitoring female sexual hormones during high-altitude field studies with the employed kit is feasible and provides physiologically plausible trends of hormone levels over the menstrual cycle. Our data provide a valuable basis for designing further studies to evaluate AMS susceptibility in women.</p>","PeriodicalId":73087,"journal":{"name":"Frontiers in global women's health","volume":"6 ","pages":"1544832"},"PeriodicalIF":2.3000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11994732/pdf/","citationCount":"0","resultStr":"{\"title\":\"Monitoring sexual hormones in women going to high altitude-a pilot study.\",\"authors\":\"Aijan Taalaibekova, Michelle Meyer, Stefanie Ulrich, Gulzada Mirzalieva, Maamed Mademilov, Mona Lichtblau, Cornelia Betschart, Talant M Sooronbaev, Silvia Ulrich, Konrad E Bloch, Michael Furian\",\"doi\":\"10.3389/fgwh.2025.1544832\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The susceptibility to acute mountain sickness (AMS) in relation to sexual hormones in women remains elusive, partly because hormones could not be conveniently measured. We evaluated a novel kit for self-monitoring sexual hormones in women and recorded AMS incidence during high-altitude sojourns.</p><p><strong>Methods: </strong>Two groups of healthy, premenopausal women, mean ± SD age 23.1 ± 2.3 years, residing <1,000 m underwent baseline evaluations at 760 m before travelling to and staying for 2 days and nights (48 h) at 3,100 m or 3,600 m, respectively. Participants self-monitored morning urine sexual hormone concentrations (estrone-1-glucuronide, E1G, pregnanediol-3-alpha-glucuronide, PdG, and luteinizing hormone, LH) daily for 30d including altitude sojourns using the simple \\\"<i>Proov</i>\\\" kit (MFB Fertility Inc). Follicular and luteal menstrual cycle phases detected by LH peak, altitude-related adverse health effects (ARAHE), AMS [Lake Louise score 2018 (LLS) ≥ 3 points including headache] and pulse oximetry (SpO<sub>2</sub>) were assessed.</p><p><strong>Results: </strong>1,172 of 1,250 (93.8%) hormone measurements were successful, 78 of 1,250 (6.2%) failed due to nonadherence or technical failure. At 3,600 m, mean differences in urinary PdG concentration were 3.8 mcg/ml (95% CI, 0.6-7.1) between luteal and follicular cycle phases. At 3,100 m, corresponding difference was 8.5 mcg/ml (95% CI, 5.0-12.0). At 3,100 m, 9 of 21 (43%) women were diagnosed with AMS with SpO<sub>2</sub> of 93.0 ± 1.6% and LLS of 0.3 ± 1.4 in the morning after the first night. At 3,600 m, 12 of 21 (57%) women had AMS (<i>p</i> = 0.355 vs. 3,100 m) with SpO<sub>2</sub> of 86.8 ± 1.8% (<i>p</i> < 0.05 vs. 3,100 m) and LLS of 1.9 ± 1.4 (<i>p</i> < 0.05 vs. 3,100 m).</p><p><strong>Conclusion: </strong>Self-monitoring female sexual hormones during high-altitude field studies with the employed kit is feasible and provides physiologically plausible trends of hormone levels over the menstrual cycle. Our data provide a valuable basis for designing further studies to evaluate AMS susceptibility in women.</p>\",\"PeriodicalId\":73087,\"journal\":{\"name\":\"Frontiers in global women's health\",\"volume\":\"6 \",\"pages\":\"1544832\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-03-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11994732/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in global women's health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3389/fgwh.2025.1544832\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in global women's health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fgwh.2025.1544832","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
Monitoring sexual hormones in women going to high altitude-a pilot study.
Background: The susceptibility to acute mountain sickness (AMS) in relation to sexual hormones in women remains elusive, partly because hormones could not be conveniently measured. We evaluated a novel kit for self-monitoring sexual hormones in women and recorded AMS incidence during high-altitude sojourns.
Methods: Two groups of healthy, premenopausal women, mean ± SD age 23.1 ± 2.3 years, residing <1,000 m underwent baseline evaluations at 760 m before travelling to and staying for 2 days and nights (48 h) at 3,100 m or 3,600 m, respectively. Participants self-monitored morning urine sexual hormone concentrations (estrone-1-glucuronide, E1G, pregnanediol-3-alpha-glucuronide, PdG, and luteinizing hormone, LH) daily for 30d including altitude sojourns using the simple "Proov" kit (MFB Fertility Inc). Follicular and luteal menstrual cycle phases detected by LH peak, altitude-related adverse health effects (ARAHE), AMS [Lake Louise score 2018 (LLS) ≥ 3 points including headache] and pulse oximetry (SpO2) were assessed.
Results: 1,172 of 1,250 (93.8%) hormone measurements were successful, 78 of 1,250 (6.2%) failed due to nonadherence or technical failure. At 3,600 m, mean differences in urinary PdG concentration were 3.8 mcg/ml (95% CI, 0.6-7.1) between luteal and follicular cycle phases. At 3,100 m, corresponding difference was 8.5 mcg/ml (95% CI, 5.0-12.0). At 3,100 m, 9 of 21 (43%) women were diagnosed with AMS with SpO2 of 93.0 ± 1.6% and LLS of 0.3 ± 1.4 in the morning after the first night. At 3,600 m, 12 of 21 (57%) women had AMS (p = 0.355 vs. 3,100 m) with SpO2 of 86.8 ± 1.8% (p < 0.05 vs. 3,100 m) and LLS of 1.9 ± 1.4 (p < 0.05 vs. 3,100 m).
Conclusion: Self-monitoring female sexual hormones during high-altitude field studies with the employed kit is feasible and provides physiologically plausible trends of hormone levels over the menstrual cycle. Our data provide a valuable basis for designing further studies to evaluate AMS susceptibility in women.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
